Enara Bio Ltd, a UK cancer company, has appointed Sophie Papa as chief medical officer to help advance the company’s T cell receptor (TCR) therapies against cancer. She joins from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust where she was a clinical reader in immuno-oncology and consultant medical oncologist. Her particular focus is the design and delivery of first-in-human studies of T cell therapies for solid tumours. Enara is characterising immunotherapy targets arising from altered cellular processes in cancer cells.
Dr Papa completed her medical training at the University of Oxford and Imperial College London and went on to complete a PhD in solid tumour CAR T cell immunotherapy at King’s College London.
Enara Bio announced the appointment on 1 February 2022.
Copyright 2022 Evernow Publishing Ltd